Cyramza ® (ramucirumab)

För fullständig produktresumé för Cyramza® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Cyramza® (ramucirumab): Användning med COVID-19-vacciner

Användningen av vacciner mot SARS-CoV-2 hos patienter som behandlas med ramucirumab har inte studerats.

Administration of COVID-19 Vaccines to Patients Receiving Ramucirumab

The use of vaccines against SARS-CoV-2 in patients treated with ramucirumab has not been studied.

Severe acute respiratory syndrome coronavirus 2 is an emerging virus that has caused the recent COVID-19 pandemic. There are several vaccines against SARS-CoV-2 currently available, and others are under development.1,2

SARS-CoV-2 Vaccination With Ramucirumab

The use of a SARS-CoV-2 vaccine in patients treated with Cyramza (ramucirumab) has not been studied by Lilly.

Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with Cyramza should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of risk factors of the patient as well as the risks and benefits of vaccination. Consultation with an infectious disease expert may be helpful in high-risk or emergency situations such as the current COVID-19 pandemic.

Infectious Disease Resources for COVID-19 Vaccines

For the most up-to-date information regarding each vaccine in development, please check the World Health Organization and Centers for Disease Control information at

https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

and

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html.

Additional information and considerations for the use of a SARS-CoV-2 vaccine in patients being treated for cancer is available from ESMO at: https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination.

References

1. Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y

2. Jackson LA, Anderson EJ, Rouphael NG, et al; mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;383(20):1920-1931. https://doi.org/10.1056/NEJMoa2022483

Glossary

COVID-19 = coronavirus disease 2019

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

Datum fӧr senaste ӧversyn January 05, 2021


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Klicka för att chatta är tillgänglig

Klicka för att chatta är offline

Skriv din fråga till oss